ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
about
DNA repair gene ERCC1 polymorphisms and glioma susceptibility among Chinese population: a meta-analysisRecent applications of chemosensitivity tests for colorectal cancer treatmentOverexpression of Rab1B and MMP9 predicts poor survival and good response to chemotherapy in patients with colorectal cancer.ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon CancerERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.Using Molecular Markers to Guide Therapy of Metastatic Colorectal CancerMolecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancerOrganic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer.Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent.A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer.A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.Differential Regulation of LET-7 by LIN28B Isoform-specific Functions.Tumor Molecular Profiling for an Individualized Approach to the Treatment of Hepatocellular Carcinoma: A Patient Case Study.
P2860
Q26784345-935AA849-E4A0-450B-90C4-9915F50A3520Q26851075-A9D3929D-E6AB-419F-92D3-9C4BB8EAEF84Q33563652-0184BF49-83AC-41C9-875C-50D683C4104CQ35666148-71C2ADB9-53AF-4148-B81A-8CA3E44F6FB7Q35833376-1B1CE1AB-F0DD-47CB-BF99-58379824EE32Q35932040-E0A86E16-B50E-4537-915C-B4BB1DB4952BQ36341759-80F29C37-0B6F-4E5E-91BE-E7C170A91BBAQ36843773-093DACBC-CE64-4DFF-9345-68A500BE619AQ37098312-D2FF0B12-FFE7-45BC-8E8C-7D33D6ED8B94Q37452215-198FB9D7-4C82-4B88-BD53-A877B93DA677Q37708015-E901C838-04E8-402E-9973-0FC1EE09579AQ38641139-22EAFB24-F6DF-467E-9C7D-734E059F301AQ38786707-64DB4F1D-ED8E-44E9-96E1-FB7018AE6481Q38835268-1D0B9487-83BC-40F9-A684-BC30188CF623Q41056921-AF2631FC-4D1A-4ABC-AA5F-3D08F8662371Q41686298-AED00346-CEBE-4B17-8216-FC365FFE73CDQ42084826-7FD77257-BE9C-442E-8AE5-53DE2050A3A9Q47110205-8D58B1B8-80D5-44D7-A762-E5EEA74A98DEQ50059044-82703584-B0E3-4286-95DB-1A7D03D60AF7Q55709145-FC04494A-A71C-42CE-86D4-BA689AFEB643
P2860
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
ERCC1, defective mismatch repa ...... in-based adjuvant chemotherapy
@en
type
label
ERCC1, defective mismatch repa ...... in-based adjuvant chemotherapy
@en
prefLabel
ERCC1, defective mismatch repa ...... in-based adjuvant chemotherapy
@en
P2093
P2860
P356
P1476
ERCC1, defective mismatch repa ...... in-based adjuvant chemotherapy
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2013.83
P407
P577
2013-03-12T00:00:00Z